Med J Aust 2025; 223 (8): 440-440. || doi: 10.5694/mja2.70063 Published online: 20 October 2025 To the Editor: We read with interest the study by Grzeskowiak and colleagues reviewing the concurrent prescription of teratogenic medications and Pharmaceutical Benefits Scheme subsidised long‐acting reversible contraception (LARC).1 The authors concluded that the rates of concurrent dispensation were “suboptimal”, with particular focus on dermatology practice in Australia.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Michelle
Contact Michelle, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack